Conjugates of group A and W135 capsular polysaccharides of Neisseria meningitidis bound to recombinant Staphylococcus aureus enterotoxin C1: Preparation, physicochemical characterization, and immunological properties in mice

Infection and Immunity

Volumn 73, Issue 12, 2005, Pages 7887-7893

  Jin, Zhigang ^a   Bohach, Gregory A ^c   Shiloach, Joseph ^b   Norris, Scott E ^d   Freedberg, Darón I ^d   Deobald, Claudia ^c   Coxon, Bruce ^a   Robbins, John B ^a   Schneerson, Rachel ^a  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^c UNIVERSITY OF IDAHO   (United States)

^d CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 CYANO 4 DIMETHYLAMINOPYRIDINIUM TETRAFLUOROBORATE; BACTERIUM LIPOPOLYSACCHARIDE; IMMUNOGLOBULIN G ANTIBODY; NEISSERIA MENINGITIDES GROUP A CAPSULAR POLYSACCHARIDE; NEISSERIA MENINGITIDES W135 CAPSULAR POLYSACCHARIDE; PHOSPHATE BUFFERED SALINE; STAPHYLOCOCCUS ENTEROTOXIN C1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIBODY DETECTION; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; GEL PERMEATION CHROMATOGRAPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNE RESPONSE; IMMUNOGENICITY; IONIC STRENGTH; LIGHT SCATTERING; NEISSERIA MENINGITIDIS; NONHUMAN; PH MEASUREMENT; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; SYNTHESIS; ULTRASOUND;

ANIMALS; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACTERIAL CAPSULES; ENTEROTOXINS; MENINGOCOCCAL VACCINES; MICE; MICE, INBRED STRAINS; NEISSERIA MENINGITIDIS, SEROGROUP A; NEISSERIA MENINGITIDIS, SEROGROUP W-135; NEUTRALIZATION TESTS; POLYSACCHARIDES, BACTERIAL; RECOMBINANT PROTEINS; VACCINES, CONJUGATE;

EID: 28444473467     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/IAI.73.12.7887-7893.2005     Document Type: Article

References (42)

1. Aguilera, J. F., A. Perrocheau, C. Meffre, S. Hahne, et al. 2002. Outbreak of serogroup W135 meningococcal disease after the Hajj pilgrimage, Europe, 2000. Emerg. Infect. Dis. 8:761-767.
2. Alexander, H. E., G. Leidy, and C. Macpherson. 1946. Production of types A, B, C, D, E, and F, Haemophilus influenzae antibody for diagnostic and therapeutic purposes. J. Immunol. 54:207-214.
3. Bednar, B., and J. P. Hennessey, Jr. 1993. Molecular size analysis of capsular polysaccharide preparations from Streptococcus pneumoniae. Carbohydr. Res. 243:115-130.
4. Berry, D. S., F. Lynn, C. H. Lee, C. E. Frasch, and M. C. Bash. 2002. Effect of acetylarion of Neisseria meningitidis serogroup A capsular polysaccharide on development of functional immune response. Infect. Immun. 70:3707-3713.
5. Bohach, G. A., and P. M. Schlievert. 1987. Expression of staphylococcal enterotoxin C1 in Escherichia coli. Infect. Immun. 55:428-432.
6. Bohach, G. A., C. J. Hovde, J. P. Handley, and P. M. Schlievert. 1988. Cross-neutralization of staphylococcal and streptococcal pyrogenic toxins by monoclonal and polyclonal antibodies. Infect. Immun. 56:400-404.
7. Brawley, R. E. 1982. Neisseria meningitidis W135 disease. JAMA 247:2779.
8. Campagne, G., A. Gaba, P. Fahre, A. Schuchat, R. Ryall. D. Boulanger, M. Bybel, G. Carlone, P. Briantis, B. Ivanoff, B. Xerri, and J.-P. Chippaux. 2000. Safety and immunogenicity of three doses of a Neisseria meningitidis A+C diphtheria conjugate vaccine in infants from Niger. Pediatr. Infect. J. 19: 144-150.
9. Centers for Disease Control and Prevention/MMER. 2000. Serogroup W-135 meningococcal disease among travelers returning from Saudi Arabia-United States, 2000. JAMA 283:2647.
10. Chi, Y. I., I. Sadler, L. M. Jablonski, S. D. Callantine, C. F. Deobald, C. V. Stauffacher, and G. A. Bohach. 2002. Zinc-mediated dimerization and its effect on activity and conformation of staphylococcal enterotoxin type C. J. Biol. Chem. 277:22839-22846.
11. D'ambra, A. J., J. E. Baugher, P. E. Concannon, R. A. Pon, and F. Michon. 1997. Direct and indirect methods for molar-mass analysis of fragments of the capsular polysaccharide of Haemophilus influenzae type b. Anal. Biochem. 250:228-236.
12. Decosas, J., and J. B. Koama. 2002. Chronicle of an outbreak foretold: meningococcal meningitis W135 in Burkina Faso. Lancet Infect. Dis. 2:763-765.
13. Denis, F., J. L. Rey, A. Amadou, P. Saliou, M. Prince-David, S. M'Boup, M. Cadox, I. D. Mar, and J. Etienne. 1982. Emergence of meningitis caused by W 135 subgroup in Africa. Lancet ii:1135-1136.
14. Fairley, C. K., N. Begg, N. Borrow, A. J. Fox, D. M. Jones, and K. Cartwright. 1996. Conjugate meningococcal serogroup A and C vaccine: reactogenicity and immunogenicity in United Kingdom infants. J. Infect. Dis. 174:1360-1363.
15. Gupta, R. K., W. Egan, D. A. Bryla, J. B. Robbins, and S. C. Szu. 1995. Comparative immunogenicity of conjugates of Escherichia coli O111 O-specific polysaccharide, prepared by treatment with acetic acid or hydrazine, bound to tetanus toxoid by two synthetic schemes. Infect. Immun. 63:2805-2810.
16. Hennessey, J. P., Jr., B. Bednar, and V. Manam. 1993. Molecular size analysis of Haemophilus influenzae type b capsular polysaccharide. J. Liquid Chromatogr. 16:1715-1729.
17. Hestrin, S. 1949. The reaction of acetylcholine and other carboxylic acid derivatives with hydroxylamine, and its analytical application. J. Biol. Chem. 180:249-261.
18. Jin, Z., C. Chu, J. B. Robbins, and R. Schneerson. 2003. Preparation and characterization of group A meningococcal capsular polysaccharide conjugates and evaluation of their immunogenicity in mice. Infect. Immun. 71: 5115-5120.
19. Joseph, H., R. Ryall, M. Bybel, T. Papa, J. MacLennan, J. Buttery, and R. Borrow. 2003. Immunogenicity and immunological priming of the serogroup A portion of a bivalent meningococcal A/C conjugate vaccine in 2-year-old children. J. Infect. Dis. 187:1142-1146.
20. Lapeysonnie, L. 1963. Cerebrospinal meningitis in Africa. Bull. W. H. O. 28(Suppl.):53-114.
21. Leech, A., P. A. Twumasi, S. Kumah, W. S. Banya, D. E. Libutti, G. N. Carlone, and B. M. Greenwood. 1997. Induction of immunologic memory in Gambian children by vaccination in infancy with a group A plus group C meningococcal polysaccharide-protein conjugate vaccine. J. Infect. Dis. 175:200-204.
22. Lieberman, J. M., S. S. Chiu, V. K. Wong, S. Patridge, S. J. Chang, C. Y. Chiu, L. L. Gheesling, G. M. Carlone, and J. I. Ward. 1996. Safety and immunogenicity of serogroup A/C Neisseria meningitidis oligosaccharide-protein conjugate vaccine in young children. JAMA 275:1499-1503.
23. Lingappa, J. R., A. M. Al-Rabeah, R. Hajjeh, T. Mustafa, A. Fatani, T. Al-Bassam, A. Badukhan, A. Turkistani, S. Makki, N. Al-Hamdan, M. Al-Jeffri, Y. Al Mazrou, B. A. Perkins, T. Popovic, L. W. Mayer, and N. E. Rosenstein. 2003. Serogroup W-135 meningococcal disease during the Hajj, 2000. Emerg. Infect. Dis. 9:665-671.
24. Longword, E., P. Fernstein, T. L. Mininni, U. Vogel, H. Claus, E. Kaczmarski, and R. Borrow. 2002. O-acetylation status of the capsular polysaccharides of systemic infections of groups Y and 135 meningococci from the United Kingdom. FEMS. Immunol. Med. Microbiol. 32:119-123.
25. (swsl)Orskov, F., I. (swsl)Orskov, A. Sutton, R. Schneerson, W. Lin, W. Egan, G. E. Hoff, and J. B. Robbins. 1979. Form variation in Escherichia coli K1: determined by O-acetylation of the capsular polysaccharide. J. Exp. Med. 149:669-685.
26. Peltola, H., A. Safary, H. Kayhty, V. Karanko, and F. E. Andre. 1985. Evaluation of two tetravalent (ACYW135) meningococcal vaccines in infants and small children: a clinical study comparing immunogenicity of O-acetyl-negative and O-acetyl-positive group C polysaccharides. Pediatr. 76:91-96.
27. Rennels, M., J. King, R. Ryall, T. Papa, and J. Froeschle. 2004. Dose escalation, safety and immunogenicity study of four dosages of a tetravalent meningococcal polysaccharide diphtheria toxoid conjugate vaccine in infants. Pediatr. Infect. Dis. J. 23:429-435.
28. Robbins, J. B., R. Schneerson, E. C. Gotschlich, I. Mohammed, A. Nasidi, J. P. Chippaux, L. Bernardine, and M. A. Maiga. 2003. Meningococcal meningitis in sub-Saharan Africa: the case for mass and routine vaccination with available polysaccharide vaccines. Bull. W. H. O. 81:745-755.
29. Sanborn, W. R., Z. Benčić, B. Cyjetanović, E. C. Gotschlich, and T. M. Pollock. 1972. Trial of a serogroup A meningococcus polysaccharide vaccine in Nigeria. Prog. Immunobiol. Standard 5:497-505.
30. Szu, S. C., G. Zon, R. Schneerson, and J. B. Robbins. 1986. Ultrasonic irradiation of bacterial polysaccharide: characterization of the depolymerized products and some applications of the process. Carbohydr. Res. 152:7-20.
31. Taha, M. K., I. Parent Du Chatelet, M. Schlumberger, I. Sanou, S. Djibo, F. de Chabalier, and J. M. Alonso. 2002. Neisseria meningitidis serogroups W135 and A were equally prevalent among meningitis cases occurring at the end of the 2001 epidemics in Burkina Faso and Niger. J. Clin. Microbiol. 40:1083-1084.
32. Tiesjema, R., E. C. Beuvery, and B. J. te Pas. 1977. Enhanced stability of meningococcal polysaccharide vaccine by using lactose as a menstrum for lyophilization. Bull. W. H. O. 55:43-48.
33. Twumasi, P. A., S. Kumah, A. Leach, T. J. D. O'Dempsey, S. J. Ceesay, J. Todd, C. V. Broome, G. M. Carlone, L. B. Pais, P. K. Holder, B. D. Plikaytis, and B. M. Greenwood. 1995. A trial of group A plus group C meningococcal polysaccharide-protein conjugate vaccine in African infants. J. Infect. Dis. 171:632-638.
34. Vann, W. F., T.-Y. Liu, and J. B. Robbins. 1976. Bacillus pumilus polysaccharide cross-reactive with meningococcal group A polysaccharide. Infect. Immun. 13;1654-1662.
35. 135Y) menngococcal vaccines containing O-acetyl-negative or O-acetyl-positive group C polysaccharide. Infect. Immun. 42:599-604.
36. Wilder-Smith, A., T. M. Barkham, S. K. Chew, and N. I. Paton. 2003. Absence of Neisseria meningitidis W-135 electrophoretic type 37 during the Hajj, 2002. Emerging Infect. Dis. 9:734-737.
37. World Health Organization. 1999. Group A and C meningococcal vaccines. Wkly. Epidemiol. Rec. 74:297-303.
38. World Health Organization. 2001. Meningococcal disease, serogroup W135. Wkly. Epidemiol. Rec. 76:141-142.
39. World Health Organization. 2002. Meningococcal disease, serogroup W135, Burkina Faso: preliminary report. Wkly. Epidemiol. Rec. 77:152-155.
40. World Health Organization. 2002. Urgent call for action on meningitis in Africa-vaccine price and shortage are major obstacles. Wkly. Epidemiol. Rec. 77:330-331.
41. World Health Organization. 1976. Requirements for meningococcal polysaccharide vaccine. Tech. Rep. Ser. 594:50-75.
42. World Health Organization. 1980. Requirements for meningococcal polysaccharide vaccine. Tech. Rep. Ser. 658:174-175.